Fluoxetine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fluoxetine: From Major Depressive Disorder to Schizotypal Personality Disorder
One-Sentence Summary
Fluoxetine is a classic SSRI, originally developed and established for the treatment of major depressive disorder. The TxGNN model's top-ranked prediction suggests possible efficacy for Schizotypal Personality Disorder, but this direction is currently supported only by 10 older publications (open-label studies, case reports, and reviews) and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder (well-established SSRI indication; no licensed indication text available in this evidence pack) |
| Predicted New Indication | Schizotypal Personality Disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap, DrugBank query pending). Based on general pharmacological knowledge, fluoxetine is a selective serotonin reuptake inhibitor (SSRI) with well-established efficacy in major depressive disorder and several other serotonin-mediated conditions (panic disorder, OCD, bulimia nervosa).
Schizotypal personality disorder is a Cluster A condition characterized by cognitive-perceptual distortions, social anxiety, and comorbid mood/anxiety symptoms. The theoretical rationale for SSRI use rests on serotonergic modulation of these cognitive-perceptual features and treatment of frequently comorbid depression/anxiety — not on a validated, disorder-specific mechanism. Notably, no controlled trial has ever directly tested fluoxetine against schizotypal PD as a primary endpoint; the supporting literature consists mainly of small, non-blinded studies from the early 1990s in mixed borderline/schizotypal populations, plus later narrative reviews of Cluster A pharmacotherapy in general. One case report additionally describes a schizotypal patient developing transient psychosis on fluoxetine, indicating the evidence base is not uniformly favorable.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9448667 | 1998 | Retrospective cohort | J Clin Psychiatry | Review of psychopharmacologic treatment in borderline/schizotypal PD; no single agent of choice, response varies by symptom cluster |
| 1853957 | 1991 | Open-label study | Am J Psychiatry | 12-week open trial (n=22, borderline/schizotypal PD); fluoxetine reduced self-injury and symptom checklist scores regardless of diagnosis |
| 29955451 | 2016 | Review | Ment Health Clin | Reviews pharmacologic treatment options across Cluster A personality disorders (paranoid, schizoid, schizotypal) |
| 8227492 | 1993 | Review | J Clin Psychopharmacol | Conceptual framework for personality disorder pharmacotherapy; pre-DSM-III evidence base, hard to interpret |
| 12214786 | 2002 | Review | Psychol Med | Examines stability of personality disorder diagnoses in depressed outpatients before/after fluoxetine treatment |
| 9664779 | 1998 | Case report | Psychosomatics | Transient psychosis with psychogenic polydipsia in a schizotypal patient taking fluoxetine — a specific safety signal in this population |
| 33634761 | 2021 | Case report | CNS Neurol Disord Drug Targets | Catatonia managed with asenapine (not fluoxetine) in a patient with schizotypal PD, psychotic depression, and COVID-19 septic shock |
| 15209835 | 2004 | Cohort study | Aust N Z J Psychiatry | Compares personality traits/outcomes between bipolar II and major depression; not specific to schizotypal PD treatment |
| 7635854 | 1995 | Cohort study | J Clin Psychiatry | Investigates predictors of drug treatment response in OCD; only tangentially related to schizotypal PD |
| 18805590 | 2009 | Cohort study | J Affect Disord | 18-month depression treatment outcome study on relapse/recovery predictors; not specific to schizotypal PD |
Germany Market Information
Fluoxetine currently has no marketing authorization on file for the German market (0 licenses). No product table is available for this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
(Note: safety.key_warnings, safety.contraindications, and DDI data are all currently unavailable — flagged as a Blocking data gap (DG001), meaning this candidate cannot yet enter the S1 safety pre-screening stage. Separately, literature evidence for this indication includes at least one case report of transient psychosis in a schizotypal patient on fluoxetine — see 9664779 above — which warrants specific attention if this indication is pursued further.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for fluoxetine in schizotypal personality disorder is limited to small, decades-old open-label studies and general reviews (Evidence Level L4), with no clinical trials and no disorder-specific mechanistic validation. Combined with a Blocking data gap on TFDA/label warnings and contraindications (DG001), this candidate cannot yet proceed to a safety pre-screening (S1) evaluation.
To proceed, the following is needed:
- TFDA/BfArM label warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- A controlled or at least prospective study specifically targeting schizotypal PD as primary endpoint
- Clarification of the psychosis signal reported in schizotypal patients on fluoxetine (PMID 9664779)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.